I don't blindly follow NP. He could do a better j
Post# of 154001
(Total Views: 403)
Posted On: 09/02/2019 1:00:33 PM
Re: Coco Beans #7130
I don't blindly follow NP. He could do a better job, for sure. So could 99% of folks in managerial positions in every industry. But the hatred some shareholders have for NP seems irrational.
He *has* accomplished a great deal, albeit slower than we wanted and with too many missed (or late) promises along the way, and we're on the cusp of BLA completion and FDA approval at a price-tag most biotechs could only dream of. So my argument all along has been to wait and see if NP delivers the BLA. Like Misui said, it could be a little late, say Oct, because we are dealing with the notoriously erratic FDA. If NP delivers, he's alright with me. If we hit Nov and still no BLA completion, by all means replace him.
Let's be honest, most of the NP critique is because flippers and shorts see him as the company's achilles heel. He's an easy target so if they convince new shareholders or those doing DD on Cytodyn, it's an effective way to induce selling or scare off new buying.
He *has* accomplished a great deal, albeit slower than we wanted and with too many missed (or late) promises along the way, and we're on the cusp of BLA completion and FDA approval at a price-tag most biotechs could only dream of. So my argument all along has been to wait and see if NP delivers the BLA. Like Misui said, it could be a little late, say Oct, because we are dealing with the notoriously erratic FDA. If NP delivers, he's alright with me. If we hit Nov and still no BLA completion, by all means replace him.
Let's be honest, most of the NP critique is because flippers and shorts see him as the company's achilles heel. He's an easy target so if they convince new shareholders or those doing DD on Cytodyn, it's an effective way to induce selling or scare off new buying.
(3)
(0)